A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.
20 Jan, 2022 | 09:30h | UTCEffectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine
Commentary on Twitter
In two matched retrospective cohort studies comparing BNT162b2 and mRNA-1273, both were highly effective at preventing hospitalization & death. Breakthrough infections were lower among those who received mRNA-1273 than those who received BNT162b2. https://t.co/wgkrzfLNHz pic.twitter.com/E8hXIDFqWW
— NEJM (@NEJM) January 19, 2022